2.1
Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'.
2 Information about blinatumomab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for blinatumomab.
Price
2.3
The list price of blinatumomab is £2,017 per 38.5-microgram vial (excluding VAT; BNF online, accessed February 2025).
2.4
The company has a commercial arrangement. This makes blinatumomab available to the NHS with a discount. The size of the discount is commercial in confidence.